

# **RUNX1 mRNA translation is inhibited by miR-17, miR-18a, miR-20a, miR-27a, miR- 106a, miR-215, miR-302b, miR-378 and miR-675**

Chuang, L.S., Ito, Y., Orlic-Milacic, M.

European Bioinformatics Institute, New York University Langone Medical Center, Ontario Institute for Cancer Research, Oregon Health and Science University.

The contents of this document may be freely copied and distributed in any media, provided the authors, plus the institutions, are credited, as stated under the terms of [Creative Commons Attribution 4.0 International \(CC BY 4.0\) License](#). For more information see our [license](#).

## Introduction

Reactome is open-source, open access, manually curated and peer-reviewed pathway database. Pathway annotations are authored by expert biologists, in collaboration with Reactome editorial staff and cross-referenced to many bioinformatics databases. A system of evidence tracking ensures that all assertions are backed up by the primary literature. Reactome is used by clinicians, geneticists, genomics researchers, and molecular biologists to interpret the results of high-throughput experimental studies, by bioinformaticians seeking to develop novel algorithms for mining knowledge from genomic studies, and by systems biologists building predictive models of normal and disease variant pathways.

The development of Reactome is supported by grants from the US National Institutes of Health (P41 HG003751), University of Toronto (CFREF Medicine by Design), European Union (EU STRP, EMI-CD), and the European Molecular Biology Laboratory (EBI Industry program).

## Literature references

- Fabregat, A., Sidiropoulos, K., Viteri, G., Forner, O., Marin-Garcia, P., Arnau, V. et al. (2017). Reactome pathway analysis: a high-performance in-memory approach. *BMC bioinformatics*, 18, 142. [↗](#)
- Sidiropoulos, K., Viteri, G., Sevilla, C., Jupe, S., Webber, M., Orlic-Milacic, M. et al. (2017). Reactome enhanced pathway visualization. *Bioinformatics*, 33, 3461-3467. [↗](#)
- Fabregat, A., Jupe, S., Matthews, L., Sidiropoulos, K., Gillespie, M., Garapati, P. et al. (2018). The Reactome Pathway Knowledgebase. *Nucleic Acids Res*, 46, D649-D655. [↗](#)
- Fabregat, A., Korninger, F., Viteri, G., Sidiropoulos, K., Marin-Garcia, P., Ping, P. et al. (2018). Reactome graph database: Efficient access to complex pathway data. *PLoS computational biology*, 14, e1005968. [↗](#)

Reactome database release: 70


This document contains 1 reaction ([see Table of Contents](#))

# RUNX1 mRNA translation is inhibited by miR-17, miR-18a, miR-20a, miR-27a, miR-106a, miR-215, miR-302b, miR-378 and miR-675 [↗](#)

**Stable identifier:** R-HSA-8935785

**Type:** omitted

**Compartments:** cytosol, nucleoplasm



Several microRNAs inhibit RUNX1 mRNA translation without affecting RUNX1 mRNA levels and are thus assumed to function as components of the nonendonucleolytic RISC. These microRNAs include miR 17, miR 20a and miR 106a (Fontana et al. 2007), miR 27a (Ben-Ami et al. 2009), miR 378a (Browne et al. 2016). As RUNX1 directly regulates transcription of the MIR27A gene, RUNX1 and MIR27A constitute a negative feedback loop involved in megakaryocyte differentiation and may regulate the switch between megakaryocytic and erythroid lineages (Ben Ami et al. 2009).

Inhibition of RUNX1 mRNA translation by other microRNAs results in decreased RUNX1 mRNA levels and these microRNAs are therefore assumed to function as components of the endonucleolytic RISC but it is possible that they additionally function as components of nonendonucleolytic RISC. MicroRNAs in this group include miR-18a (Miao et al. 2015), miR-215 (Li et al. 2016), miR-302b (Ge et al. 2014) and miR 675 (Zhuang et al. 2014).

MicroRNA miR 215 binding to the 3'UTR of RUNX1 mRNA inhibits RUNX1 mRNA translation and reduces RUNX1 mRNA levels (Li et al. 2016).

## Literature references

- Zhuang, M., Gao, W., Xu, J., Wang, P., Shu, Y. (2014). The long non-coding RNA H19-derived miR-675 modulates human gastric cancer cell proliferation by targeting tumor suppressor RUNX1. *Biochem. Biophys. Res. Commun.*, 448, 315-22. [↗](#)
- Li, N., Zhang, QY., Zou, JL., Li, ZW., Tian, TT., Dong, B. et al. (2016). miR-215 promotes malignant progression of gastric cancer by targeting RUNX1. *Oncotarget*, 7, 4817-28. [↗](#)
- Ben-Ami, O., Pencovich, N., Lotem, J., Levanon, D., Groner, Y. (2009). A regulatory interplay between miR-27a and Runx1 during megakaryopoiesis. *Proc. Natl. Acad. Sci. U.S.A.*, 106, 238-43. [↗](#)
- Ge, T., Yin, M., Yang, M., Liu, T., Lou, G. (2014). MicroRNA-302b suppresses human epithelial ovarian cancer cell growth by targeting RUNX1. *Cell. Physiol. Biochem.*, 34, 2209-20. [↗](#)
- Miao, YS., Zhao, YY., Zhao, LN., Wang, P., Liu, YH., Ma, J. et al. (2015). MiR-18a increased the permeability of BTB via RUNX1 mediated down-regulation of ZO-1, occludin and claudin-5. *Cell. Signal.*, 27, 156-67. [↗](#)

## Editions

2016-09-14	Authored	Orlic-Milacic, M.
2016-12-20	Reviewed	Ito, Y., Chuang, LS.
2017-05-09	Edited	Orlic-Milacic, M.